Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announced that it has refiled its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three- and six-month periods ended March 31, 2020, following a review by the British Columbia Securities Commission. In its earlier reports of the periods mentioned, Champignon reported intangible assets in connection with its acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Information regarding those acquisitions have been restated to correct for the accounting of those acquisitions. After review, it was determined that the reported intangible assets did not meet the definition of intangible assets for the purposes of international financial reporting standards. Consequently, that information will be recorded as transaction costs in Champignon’s statement of loss and comprehensive loss. On updated reports, the net loss and comprehensive loss for the restated three-month period ended March 31, 2020, increased from $2,774,986 to $16,329,497; the numbers for the six-month period changed from $2,916,302 to $16,470,813. The release of updated figures had no impact on the company’s cash position. Furthermore, in the review it was found that a shareholder and contracted consultant was, in fact, a related party with respect to the acquisitions. Therefore, Champignon added both the proceeds paid to the consultant and the stock options issued to the consultant as related party transactions in financial reports it has refiled. All of these filings have now been completed by Champignon, and company management is working closely with the commission and the CSE to accomplish the revocation of the existing cease trade orders against the company and the filing of a new listing statement as quickly as possible.
To view the full press release, visit https://ibn.fm/0duvZ
About Champignon Brands Inc.
Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information about this company, visit www.ChampignonBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.